scholarly journals NovelN-Benzoyl-2-Hydroxybenzamide Disrupts Unique Parasite Secretory Pathway

2012 ◽  
Vol 56 (5) ◽  
pp. 2666-2682 ◽  
Author(s):  
Alina Fomovska ◽  
Qingqing Huang ◽  
Kamal El Bissati ◽  
Ernest J. Mui ◽  
William H. Witola ◽  
...  
Keyword(s):  
Secretory Pathway ◽  
Protozoan Parasite ◽  
Secretory Protein ◽  
Content Type ◽  
Apicomplexan Parasites ◽  
Dense Granules ◽  
Genome Wide ◽  
Nanomolar Range

ABSTRACTToxoplasma gondiiis a protozoan parasite that can damage the human brain and eyes. There are no curative medicines. Herein, we describe our discovery ofN-benzoyl-2-hydroxybenzamides as a class of compounds effective in the low nanomolar range againstT. gondii in vitroandin vivo. Our lead compound, QQ-437, displays robust activity against the parasite and could be useful as a new scaffold for development of novel and improved inhibitors ofT. gondii. Our genome-wide investigations reveal a specific mechanism of resistance toN-benzoyl-2-hydroxybenzamides mediated by adaptin-3β, a large protein from the secretory protein complex.N-Benzoyl-2-hydroxybenzamide-resistant clones have alterations of their secretory pathway, which traffics proteins to micronemes, rhoptries, dense granules, and acidocalcisomes/plant-like vacuole (PLVs).N-Benzoyl-2-hydroxybenzamide treatment also alters micronemes, rhoptries, the contents of dense granules, and, most markedly, acidocalcisomes/PLVs. Furthermore, QQ-437 is active against chloroquine-resistantPlasmodium falciparum. Our studies reveal a novel class of compounds that disrupts a unique secretory pathway ofT. gondii, with the potential to be used as scaffolds in the search for improved compounds to treat the devastating diseases caused by apicomplexan parasites.

scholarly journals Hydroxylamine and Carboxymethoxylamine Can Inhibit Toxoplasma gondii Growth through an Aspartate Aminotransferase-Independent Pathway

2020 ◽  
Vol 64 (3) ◽  
Author(s):  
Jixu Li ◽  
Huanping Guo ◽  
Eloiza May Galon ◽  
Yang Gao ◽  
Seung-Hun Lee ◽  
...  
Keyword(s):  
Toxoplasma Gondii ◽  
Drug Targets ◽  
Protozoan Parasite ◽  
Cell Types ◽  
Lytic Cycle ◽  
Type I ◽  
Content Type ◽  
Mechanism Of Inhibition

ABSTRACT Toxoplasma gondii is an obligate intracellular protozoan parasite and a successful parasitic pathogen in diverse organisms and host cell types. Hydroxylamine (HYD) and carboxymethoxylamine (CAR) have been reported as inhibitors of aspartate aminotransferases (AATs) and interfere with the proliferation in Plasmodium falciparum. Therefore, AATs are suggested as drug targets against Plasmodium. The T. gondii genome encodes only one predicted AAT in both T. gondii type I strain RH and type II strain PLK. However, the effects of HYD and CAR, as well as their relationship with AAT, on T. gondii remain unclear. In this study, we found that HYD and CAR impaired the lytic cycle of T. gondii in vitro, including the inhibition of invasion or reinvasion, intracellular replication, and egress. Importantly, HYD and CAR could control acute toxoplasmosis in vivo. Further studies showed that HYD and CAR could inhibit the transamination activity of rTgAAT in vitro. However, our results confirmed that deficiency of AAT in both RH and PLK did not reduce the virulence in mice, although the growth ability of the parasites was affected in vitro. HYD and CAR could still inhibit the growth of AAT-deficient parasites. These findings indicated that HYD and CAR inhibition of T. gondii growth and control of toxoplasmosis can occur in an AAT-independent pathway. Overall, further studies focusing on the elucidation of the mechanism of inhibition are warranted. Our study hints at new substrates of HYD and CAR as potential drug targets to inhibit T. gondii growth.

scholarly journals Evaluation of 4-Amino 2-Anilinoquinazolines against Plasmodium and Other Apicomplexan Parasites In Vitro and in a P. falciparum Humanized NOD-scid IL2Rγnull Mouse Model of Malaria

2018 ◽  
Vol 63 (3) ◽  
Author(s):  
Paul R. Gilson ◽  
William Nguyen ◽  
William A. Poole ◽  
Jose E. Teixeira ◽  
Jennifer K. Thompson ◽  
...  
Keyword(s):  
Mouse Model ◽  
Babesia Bovis ◽  
Parasite Line ◽  
Humanized Mouse ◽  
Humanized Mouse Model ◽  
Content Type ◽  
Apicomplexan Parasites ◽  
Micromolar Range

ABSTRACT A series of 4-amino 2-anilinoquinazolines optimized for activity against the most lethal malaria parasite of humans, Plasmodium falciparum, was evaluated for activity against other human Plasmodium parasites and related apicomplexans that infect humans and animals. Four of the most promising compounds from the 4-amino 2-anilinoquinazoline series were equally as effective against the asexual blood stages of the zoonotic P. knowlesi, suggesting that they could also be effective against the closely related P. vivax, another important human pathogen. The 2-anilinoquinazoline compounds were also potent against an array of P. falciparum parasites resistant to clinically available antimalarial compounds, although slightly less so than against the drug-sensitive 3D7 parasite line. The apicomplexan parasites Toxoplasma gondii, Babesia bovis, and Cryptosporidium parvum were less sensitive to the 2-anilinoquinazoline series with a 50% effective concentration generally in the low micromolar range, suggesting that the yet to be discovered target of these compounds is absent or highly divergent in non-Plasmodium parasites. The 2-anilinoquinazoline compounds act as rapidly as chloroquine in vitro and when tested in rodents displayed a half-life that contributed to the compound’s capacity to clear P. falciparum blood stages in a humanized mouse model. At a dose of 50 mg/kg of body weight, adverse effects to the humanized mice were noted, and evaluation against a panel of experimental high-risk off targets indicated some potential off-target activity. Further optimization of the 2-anilinoquinazoline antimalarial class will concentrate on improving in vivo efficacy and addressing adverse risk.

Insights into the Secretory Pathway, the Mechanism of Terminal Glycosylation and Intracellular Peptide Hormone Receptors from Studies on Hepatic Golgi Fractions

1981 ◽  
Vol 39 ◽  
pp. 516-519
Author(s):  
J.J.M. Bergeron ◽  
B.I. Posner ◽  
Jacques Paiement ◽  
R. Sikstrom ◽  
M. Khan
Keyword(s):  
Golgi Apparatus ◽  
Plasma Proteins ◽  
Secretory Pathway ◽  
Hormone Receptors ◽  
Peptide Hormone ◽  
Secretory Protein ◽  
Golgi Membrane ◽  
Membrane Structures

Recent studies on purified subcellular fractions of hepatic Golgi apparatus have provided insight into the functioning of the Golgi apparatus in vivo.The hepatocyte is the site of synthesis of most circulating plasma proteins. On a total protein basis, purified Golgi fractions revealed mainly secretory content (albumin, transferrin and other plasma proteins) as major constituents. After an in vivo injection of radiolabeled leucine, newly synthesized secretory protein followed a temporal route from cis to trans regions of Golgi apparatus before appearance in the plasma. This route was revealed by studies on disrupted Golgi fractions enriched in disparate regions of the Golgi apparatus.The terminal glycosylation of secretory glcyoproteins (e.g. transferrin) can be studied by observing the transfer of UDP-(3H)-galactose to endogenous acceptors within Golgi fractions. Transfer was shown to occur to a glycolipid (dolichyl galactosyl phosphate) probably on the cytosolic aspect of the Golgi membrane. Translocation of the labeled galactose across the membrane coincided with fusion of Golgi saccules in vitro. It is felt that during the process of Golgi membrane fusion, inverted lipid- micellar membrane structures translocate the dolichyl galactosyl phosphate from a cytosolic to a luminal orientation. Luminally oriented dolichyl galactosyl phosphate would then serve as substrate for galactose transfer to intraluminal glycopeptide acceptors via intraluminal galactosyl transferase enzyme.

scholarly journals Toll-Like Receptor 9 Signaling in Dendritic Cells Regulates Neutrophil Recruitment to Inflammatory Foci following Leishmania infantum Infection

2015 ◽  
Vol 83 (12) ◽  
pp. 4604-4616 ◽  
Author(s):  
Laís Sacramento ◽  
Silvia C. Trevelin ◽  
Manuela S. Nascimento ◽  
Djalma S. Lima-Jùnior ◽  
Diego L. Costa ◽  
...  
Keyword(s):  
Leishmania Infantum ◽  
Critical Role ◽  
Costimulatory Molecule ◽  
Protozoan Parasite ◽  
Neutrophil Recruitment ◽  
Content Type ◽  
Target Organs ◽  
Myd88 Signaling

Leishmania infantumis a protozoan parasite that causes visceral leishmaniasis (VL). This infection triggers dendritic cell (DC) activation through the recognition of microbial products by Toll-like receptors (TLRs). Among the TLRs, TLR9 is required for DC activation by differentLeishmaniaspecies. We demonstrated that TLR9 is upregulatedin vitroandin vivoduring infection. We show that C57BL/6 mice deficient in TLR9 expression (TLR9−/−mice) are more susceptible to infection and display higher parasite numbers in the spleen and liver. The increased susceptibility of TLR9−/−mice was due to the impaired recruitment of neutrophils to the infection foci associated with reduced levels of neutrophil chemoattractants released by DCs in the target organs. Moreover, both Th1 and Th17 cells were also committed in TLR9−/−mice. TLR9-dependent neutrophil recruitment is mediated via the MyD88 signaling pathway but is TIR domain-containing adapter-inducing interferon beta (TRIF) independent. Furthermore,L. infantumfailed to activate both plasmacytoid and myeloid DCs from TLR9−/−mice, which presented reduced surface costimulatory molecule expression and chemokine release. Interestingly, neutrophil chemotaxis was affected bothin vitroandin vivowhen DCs were derived from TLR9−/−mice. Our results suggest that TLR9 plays a critical role in neutrophil recruitment during the protective response againstL. infantuminfection that could be associated with DC activation.

Neuroendocrine secretory protein 7B2: structure, expression and functions

2001 ◽  
Vol 357 (2) ◽  
pp. 329-342 ◽  
Author(s):  
Majambu MBIKAY ◽  
Nabil G. SEIDAH ◽  
Michel CHRÉTIEN
Keyword(s):  
Secretory Pathway ◽  
Secretory Granules ◽  
Secretory Protein ◽  
Neuroendocrine Cells ◽  
High Similarity ◽  
Granule Formation ◽  
Proteolytic Activation ◽  
Polyproline Motif

7B2 is an acidic protein residing in the secretory granules of neuroendocrine cells. Its sequence has been elucidated in many phyla and species. It shows high similarity among mammals. A Pro-Pro-Asn-Pro-Cys-Pro polyproline motif is its most conserved feature, being carried by both vertebrate and invertebrate sequences. It is biosynthesized as a precursor protein that is cleaved into an N-terminal fragment and a C-terminal peptide. In neuroendocrine cells, 7B2 functions as a specific chaperone for the proprotein convertase (PC) 2. Through the sequence around its Pro-Pro-Asn-Pro-Cys-Pro motif, it binds to an inactive proPC2 and facilitates its transport from the endoplasmic reticulum to later compartments of the secretory pathway where the zymogen is proteolytically matured and activated. Its C-terminal peptide can inhibit PC2 in vitro and may contribute to keep the enzyme transiently inactive in vivo. The PC2–7B2 model defines a new neuroendocrine paradigm whereby proteolytic activation of prohormones and proneuropeptides in the secretory pathway is spatially and temporally regulated by the dynamics of interactions between converting enzymes and their binding proteins. Interestingly, unlike PC2-null mice, which are viable, 7B2-null mutants die early in life from Cushing's disease due to corticotropin (‘ACTH’) hypersecretion by the neurointermediate lobe, suggesting a possible involvement of 7B2 in secretory granule formation and in secretion regulation. The mechanism of this regulation is yet to be elucidated. 7B2has been shown to be a good marker of several neuroendocrine cell dysfunctions in humans. The possibility that anomalies in its structure and expression could be aetiological causes of some of these dysfunctions warrants investigation.

scholarly journals Guanabenz Repurposed as an Antiparasitic with Activity against Acute and Latent Toxoplasmosis

2015 ◽  
Vol 59 (11) ◽  
pp. 6939-6945 ◽  
Author(s):  
Imaan Benmerzouga ◽  
Lisa A. Checkley ◽  
Michael T. Ferdig ◽  
Gustavo Arrizabalaga ◽  
Ronald C. Wek ◽  
...  
Keyword(s):  
Translational Control ◽  
Protozoan Parasite ◽  
Empty Space ◽  
Antiparasitic Activity ◽  
Content Type ◽  
Life Threatening ◽  
Brain Cysts ◽  
The Brain

ABSTRACTToxoplasma gondiiis a protozoan parasite that persists as a chronic infection.Toxoplasmaevades immunity by forming tissue cysts, which reactivate to cause life-threatening disease during immune suppression. There is an urgent need to identify drugs capable of targeting these latent tissue cysts, which tend to form in the brain. We previously showed that translational control is critical during infections with both replicative and latent forms ofToxoplasma. Here we report that guanabenz, an FDA-approved drug that interferes with translational control, has antiparasitic activity against replicative stages ofToxoplasmaand the related apicomplexan parasitePlasmodium falciparum(a malaria agent). We also found that inhibition of translational control interfered with tissue cyst biologyin vitro.Toxoplasmabradyzoites present in these abnormal cysts were diminished and misconfigured, surrounded by empty space not seen in normal cysts. These findings prompted analysis of the efficacy of guanabenzin vivoby using established mouse models of acute and chronic toxoplasmosis. In addition to protecting mice from lethal doses ofToxoplasma, guanabenz has a remarkable ability to reduce the number of brain cysts in chronically infected mice. Our findings suggest that guanabenz can be repurposed into an effective antiparasitic with a unique ability to reduce tissue cysts in the brain.

scholarly journals New Method for the Orthogonal Labeling and Purification of Toxoplasma gondii Proteins While Inside the Host Cell

mBio ◽  
2015 ◽  
Vol 6 (2) ◽  
Author(s):  
Gregory M. Wier ◽  
Erica M. McGreevy ◽  
Mark J. Brown ◽  
Jon P. Boyle
Keyword(s):  
Toxoplasma Gondii ◽  
Host Cell ◽  
Click Reaction ◽  
Severe Disease ◽  
Protozoan Parasite ◽  
Trna Synthetase ◽  
Content Type ◽  
Fluorescent Tags

ABSTRACTToxoplasma gondiiis an obligate intracellular protozoan parasite that is capable of causing severe disease in immunocompromised humans. How T. gondii is able to modulate the host cell to support itself is still poorly understood. Knowledge pertaining to the host-parasite interaction could be bolstered by developing a system to specifically label parasite proteins while the parasite grows inside the host cell. For this purpose, we have created a strain of T. gondii that expresses a mutant Escherichia coli methionyl-tRNA synthetase (MetRSNLL) that allows methionine tRNA to be loaded with the azide-containing methionine analog azidonorleucine (Anl). Anl-containing proteins are susceptible to a copper-catalyzed “click” reaction to attach affinity tags for purification or fluorescent tags for visualization. The MetRSNLL-Anl system labels nascent T. gondii proteins in an orthogonal fashion, labeling proteins only in MetRSNLL-expressing parasites. This system should be useful for nonradioactive pulse-chase studies and purification of nascently translated proteins. Although this approach allows labeling of a diverse array of parasite proteins, secreted parasite proteins appear to be only minimally labeled in MetRSNLL-expressing T. gondii. The minimal labeling of secreted proteins is likely a consequence of the selective charging of the initiator tRNA (and not the elongator methionine tRNA) by the heterologously expressed bacterial MetRS.IMPORTANCEStudying how T. gondii modifies the host cell to permit its survival is complicated by the complex protein environment of the host cell. The approach presented in this article provides the first method for specific labeling of T. gondii proteins while the parasite grows inside the host cell. We show that this approach is useful for pulse-chase labeling of parasite proteins duringin vitrogrowth. It should also be applicable duringin vivoinfections and in other apicomplexan parasites, including Plasmodium spp.

scholarly journals In Vitro and In Vivo Activities of Sulfur-Containing Linear Bisphosphonates against Apicomplexan Parasites

2016 ◽  
Vol 61 (2) ◽  
Author(s):  
Sergio H. Szajnman ◽  
Tamila Galaka ◽  
Zhu-Hong Li ◽  
Catherine Li ◽  
Nathan M. Howell ◽  
...  
Keyword(s):  
Cryptosporidium Parvum ◽  
Etiologic Agent ◽  
Effective Concentration ◽  
Selectivity Index ◽  
Content Type ◽  
Apicomplexan Parasites ◽  
Low Toxicity ◽  
Sulfur Containing

ABSTRACT We tested a series of sulfur-containing linear bisphosphonates against Toxoplasma gondii, the etiologic agent of toxoplasmosis. The most potent compound (compound 22; 1-[(n-decylsulfonyl)ethyl]-1,1-bisphosphonic acid) is a sulfone-containing compound, which had a 50% effective concentration (EC50) of 0.11 ± 0.02 μM against intracellular tachyzoites. The compound showed low toxicity when tested in tissue culture with a selectivity index of >2,000. Compound 22 also showed high activity in vivo in a toxoplasmosis mouse model. The compound inhibited the Toxoplasma farnesyl diphosphate synthase (TgFPPS), but the concentration needed to inhibit 50% of the enzymatic activity (IC50) was higher than the concentration that inhibited 50% of growth. We tested compound 22 against two other apicomplexan parasites, Plasmodium falciparum (EC50 of 0.6 ± 0.01 μM), the agent of malaria, and Cryptosporidium parvum (EC50 of ∼65 μM), the agent of cryptosporidiosis. Our results suggest that compound 22 is an excellent novel compound that could lead to the development of potent agents against apicomplexan parasites.

scholarly journals A druggable secretory protein maturase of Toxoplasma essential for invasion and egress

eLife ◽  
2017 ◽  
Vol 6 ◽  
Author(s):  
Sunil Kumar Dogga ◽  
Budhaditya Mukherjee ◽  
Damien Jacot ◽  
Tobias Kockmann ◽  
Luca Molino ◽  
...  
Keyword(s):  
Secretory Protein ◽  
Lytic Cycle ◽  
Secretory Proteins ◽  
Isotopic Labelling ◽  
Apicomplexan Parasites ◽  
Cell Plasma ◽  
Membrane Lysis

Micronemes and rhoptries are specialized secretory organelles that deploy their contents at the apical tip of apicomplexan parasites in a regulated manner. The secretory proteins participate in motility, invasion, and egress and are subjected to proteolytic maturation prior to organellar storage and discharge. Here we establish that Toxoplasma gondii aspartyl protease 3 (ASP3) resides in the endosomal-like compartment and is crucially associated to rhoptry discharge during invasion and to host cell plasma membrane lysis during egress. A comparison of the N-terminome, by terminal amine isotopic labelling of substrates between wild type and ASP3 depleted parasites identified microneme and rhoptry proteins as repertoire of ASP3 substrates. The role of ASP3 as a maturase for previously described and newly identified secretory proteins is confirmed in vivo and in vitro. An antimalarial compound based on a hydroxyethylamine scaffold interrupts the lytic cycle of T. gondii at submicromolar concentration by targeting ASP3.

scholarly journals Dynamic tracking and identification of tissue-specific secretory proteins in the circulation of live mice

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Kwang-eun Kim ◽  
Isaac Park ◽  
Jeesoo Kim ◽  
Myeong-Gyun Kang ◽  
Won Gun Choi ◽  
...  
Keyword(s):  
Secretory Pathway ◽  
Ex Vivo ◽  
Secretory Protein ◽  
Spatiotemporal Dynamics ◽  
Whole Body ◽  
Accurate Information ◽  
Secretory Proteins ◽  
Specific Cell

AbstractSecretory proteins are an essential component of interorgan communication networks that regulate animal physiology. Current approaches for identifying secretory proteins from specific cell and tissue types are largely limited to in vitro or ex vivo models which often fail to recapitulate in vivo biology. As such, there is mounting interest in developing in vivo analytical tools that can provide accurate information on the origin, identity, and spatiotemporal dynamics of secretory proteins. Here, we describe iSLET (in situ Secretory protein Labeling via ER-anchored TurboID) which selectively labels proteins that transit through the classical secretory pathway via catalytic actions of Sec61b-TurboID, a proximity labeling enzyme anchored in the ER lumen. To validate iSLET in a whole-body system, we express iSLET in the mouse liver and demonstrate efficient labeling of liver secretory proteins which could be tracked and identified within circulating blood plasma. Furthermore, proteomic analysis of the labeled liver secretome enriched from liver iSLET mouse plasma is highly consistent with previous reports of liver secretory protein profiles. Taken together, iSLET is a versatile and powerful tool for studying spatiotemporal dynamics of secretory proteins, a valuable class of biomarkers and therapeutic targets.

Sign in / Sign up

Export Citation Format

Share Document